Natalie Marlowe
About Natalie Marlowe
Natalie Marlowe serves as the Senior Director of Scientific and Medical Affairs at DURECT Corporation, where she has worked since 2020. With a background that includes significant roles at Celera and Abbott Molecular, she has contributed to research on alcohol-associated hepatitis and has presented at international conferences.
Work at DURECT Corporation
Natalie Marlowe serves as the Senior Director of Scientific and Medical Affairs at DURECT Corporation, a position she has held since 2020. In this role, she is responsible for overseeing scientific initiatives and medical strategies within the organization. DURECT Corporation is based in Cupertino, California, and focuses on developing innovative therapeutics for various medical conditions.
Previous Experience at Celera
Prior to her current role, Natalie Marlowe worked at Celera as the Director of Product Development from 2002 to 2011. During her nine years at Celera, she contributed to the development of various products, enhancing the company's portfolio and scientific capabilities.
Experience at Abbott Molecular
From 2011 to 2020, Natalie Marlowe held the position of Associate Director at Abbott Molecular. In this role, she operated from a virtual office, managing projects and initiatives that supported the company's objectives in molecular diagnostics and related fields.
Research Contributions
Natalie Marlowe has been actively involved in research concerning alcohol-associated hepatitis. She presented her findings on the safety and efficacy of Larsucosterol at the European Association for the Study of the Liver (EASL) International Liver Congress in June 2023. Additionally, she co-authored a study on Medicare patient outcomes related to alcohol-associated hepatitis, published in March 2023, and another publication on the intersection of alcohol-associated hepatitis and COVID-19 in Alcohol: Clinical and Experimental Research (ACER) in August 2023.